EMEusebio Macete

Eusebio Macete

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eusebio Macete has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Design of a phase III multicenter trial to evaluate the efficacy of the RTS,S/AS01 malaria vaccine in children across diverse transmission settings in Africa

    by the Clinical Trials Partnership Committee, Amanda Leach, Johan Vekemans, Marc Lievens, Opokua Ofori-Anyinam, Conor Cahill, Seth Owusu-Agyei, Salim Abdulla, Eusebio Macete, Patricia Njuguna, et al.

    GlaxoSmithKline Biologicals and the PATH Malaria Vaccine Initiative are working in partnership to develop a malaria vaccine to protect infants and children living in malaria endemic regions of sub-Saharan Africa, which can be delivered through the Expanded Programme on Immunization. The RTS,S/AS candidate vaccine has been evaluated in multiple phase I/II studies and shown to have a favourable safety profile and to be well-tolerated in both adults and children. This paper details the design of the phase III multicentre efficacy trial of the RTS,S/AS01 malaria vaccine candidate, which is pivotal for licensure and policy decision-making.


  • Open Access

    A 10 year study of the cause of death in children under 15 years in Manhiça, Mozambique

    by Jahit Sacarlal, Ariel Q Nhacolo, Betuel Sigaúque, Delino A Nhalungo, Fatima Abacassamo, Charfudin N Sacoor, Pedro Aide, Sonia Machevo, Tacilta Nhampossa, Eusébio V Macete, et al.

    Approximately 46 million of the estimated 60 million deaths that occur in the world each year take place in developing countries. Further, this mortality is highest in Sub-Saharan Africa, although causes of mortality in this region are not well documented. The objective of this study is to describe the most frequent causes of mortality in children under 15 years of age in the demographic surveillance area of the Manhiça Health Research Centre, between 1997 and 2006, using the verbal autopsy tool.


  • Open Access

    Malaria in rural Mozambique. Part II: children admitted to hospital

    by Quique Bassat, Caterina Guinovart, Betuel Sigaúque, Pedro Aide, Jahit Sacarlal, Tacilta Nhampossa, Azucena Bardají, Ariel Nhacolo, Eusébio Macete, Inácio Mandomando, et al.

    Background: Characterization of severe malaria cases on arrival to hospital may lead to early recognition and improved management. Minimum community based-incidence rates (MCBIRs) complement hospital data, describing the malaria burden in the community. Methods: A retrospective analysis of all admitted malaria cases to a Mozambican rural hospital between June 2003 and May 2005 was conducted. Prevalence and case fatality rates (CFR) for each sign and symptom were calculated. Logistic regression was used to identify variables which were independent risk factors for death. MCBIRs for malaria and severe malaria were calculated using data from the Demographic Surveillance System. Results: Almost half of the 8,311 patients admitted during the study period had malaria and 13,2% had severe malaria. Children under two years accounted for almost 60% of all malaria cases. CFR for malaria was 1.6% and for severe malaria 4.4%. Almost 19% of all paediatric hospital deaths were due to malaria. Prostration (55.0%), respiratory distress (41.1%) and severe anaemia (17.3%) were the most prevalent signs among severe malaria cases. Severe anaemia and inability to look for mother's breast were independent risk factors for death in infants younger than eight months. For children aged eight months to four years, the risk factors were malnutrition, hypoglycaemia, chest indrawing, inability to sit and a history of vomiting. MCBIRs for severe malaria cases were highest in children aged six months to two years of age. MCBIRs for severe malaria per 1,000 child years at risk for the whole study period were 27 in infants, 23 in children aged 1 to <5 years and two in children aged ≥5 years. Conclusion: Malaria remains the number one cause of admission in this area of rural Mozambique, predominantly affecting young children, which are also at higher risk of dying. Measures envisaged to protect children during their first two years of life are likely to have a greater impact than at any other age.


  • Open Access

    Malaria in rural Mozambique. Part I: Children attending the outpatient clinic

    by Caterina Guinovart, Quique Bassat, Betuel Sigaúque, Pedro Aide, Jahit Sacarlal, Tacilta Nhampossa, Azucena Bardají, Ariel Nhacolo, Eusébio Macete, Inácio Mandomando, et al.

    Malaria represents a huge burden for the health care services across Africa. Describing malaria attending health services contributes to quantify the burden and describe the epidemiology and clinical presentation.


  • Open Access

    Varying efficacy of intermittent preventive treatment for malaria in infants in two similar trials: public health implications

    by Clara Menendez, David Schellenberg, Eusebio Macete, Pedro Aide, Elizeus Kahigwa, Sergi Sanz, John J Aponte, Jahit Sacarlal, Hassan Mshinda, Marcel Tanner, et al.

    Intermittent preventive treatment (IPTi) with sulphadoxine-pyrimethamine (SP) in infants resulted in different estimates of clinical malaria protection in two trials that used the same protocol in Ifakara, Tanzania, and Manhiça, Mozambique. Understanding the reasons for the discrepant results will help to elucidate the action mechanism of this intervention, which is essential for rational policy formulation.


  • Open Access

    Evaluation of two formulations of adjuvanted RTS, S malaria vaccine in children aged 3 to 5 years living in a malaria-endemic region of Mozambique: a Phase I/IIb randomized double-blind bridging trial

    by Eusebio V Macete, Jahit Sacarlal, John J Aponte, Amanda Leach, Margarita M Navia, Jessica Milman, Caterina Guinovart, Inacio Mandomando, Yolanda López-Púa, Marc Lievens, et al.

    Previous trials of the RTS, S malaria candidate vaccine have shown that this vaccine is safe, tolerated and immunogenic. The development plan for this vaccine aims at administering it in the first year of life through the Expanded Program on Immunization (EPI). The objective was to evaluate the safety and reactogenicity of RTS, S/AS02D (0.5 ml dose), a pediatric formulation of GlaxoSmithKline Biologicals' current malaria candidate vaccine RTS, S/AS02A (0.25 ml dose). A 0.5 ml dose of AS02D is composed of the same active ingredients in the same quantities as in a 0.25 ml dose of AS02A and has been developed to be easily introduced into routine EPI practices.